2024/08/16 08:08:00 | |
---|---|
Price | |
2.964 EUR | |
Difference | 0.00% (0.00) |
ISIN | NL0015436031 |
Symbol | CVAC |
Exchange | Munich |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 662 EUR |
Benchmark | GERMANY DAX |
Bid (Bid size) | - |
Ask (Ask size) | - |
Open | 2.964 EUR |
High | 2.964 EUR |
Low | 2.964 EUR |
Close (prev. day) | 2.964 EUR |
VWAP | 2.95017 EUR |
Volume (pcs) | 0 |
Trading volume | 0.00 |
Number of trades | 1 |
Last size | 0 |
Related Futures | - |
Related Options | - |
Date | Headline | Download | |
2024/08/12 |
![]() |
Global Equity Ratings |
![]() |
2024/07/24 |
![]() |
Global Equity Ratings |
![]() |
2024/07/12 |
![]() |
Global Equity Ratings |
![]() |
2024/06/21 |
![]() |
Global Equity Ratings |
![]() |
2024/06/14 |
![]() |
Global Equity Ratings |
![]() |
2024/08/16 08:08:00 | |
---|---|
Price | |
2.964 EUR | |
Difference | 0.00% (0.00) |
ISIN | NL0015436031 |
Symbol | CVAC |
Exchange | Munich |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 662 EUR |
Benchmark | GERMANY DAX |
Bid (Bid size) | - |
Ask (Ask size) | - |
Open | 2.964 EUR |
High | 2.964 EUR |
Low | 2.964 EUR |
Close (prev. day) | 2.964 EUR |
VWAP | 2.95017 EUR |
Volume (pcs) | 0 |
Trading volume | 0.00 |
Number of trades | 1 |
Last size | 0 |
6m | 1Y | 3Y | |
Perf (%) | -6.79% | -66.09% | -94.20% |
Perf (abs.) | -0.22 | -5.78 | -48.11 |
Beta | 1.10 | 1.07 | 0.91 |
Volatility | 74.79 | 69.98 | 72.01 |
Ø price 5 days | Ø volume 5 days (pcs.) | 2.984 EUR (304) |
Ø price 30 days | Ø volume 30 days (pcs.) | 3.178 EUR (6,941) |
Ø price 100 days | Ø volume 100 days (pcs.) | 3.102 EUR (3,304) |
Ø price 250 days | Ø volume 250 days (pcs.) | 4.121 EUR (1,780) |
YTD High | date | 4.756 EUR (2024/06/06) |
YTD Low | date | 2.162 EUR (2024/04/29) |
52 Weeks High | date | 8.740 EUR (2023/08/17) |
52 Weeks Low | date | 2.162 EUR (2024/04/29) |
Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
Xetra | 2024/08/16 | 17:36 | 2.928 EUR | 0.42 | 254 |
Vienna Stock Exchange | 2024/08/16 | 17:32 | 2.942 EUR | 0.00 | 5 |
Tradegate | 2024/08/16 | 22:26 | 2.944 EUR | 0.68 | 229 |
Stuttgart | 2024/08/16 | 19:26 | 2.946 EUR | 0.04 | 15 |
Nasdaq | 2024/08/16 | 22:00 | 3.24 USD | 1.68 | 4,491 |
Munich | 2024/08/16 | 08:08 | 2.964 EUR | 0.00 | 1 |
London Stock Exchange European Trade Reporting | 2024/08/16 | 17:30 | 3.21 USD | 0.00 | 2 |
Hanover | 2024/08/16 | 08:01 | 2.956 EUR | 0.00 | 3 |
Hamburg | 2024/08/16 | 13:21 | 2.98 EUR | 0.01 | 3 |
Frankfurt | 2024/08/16 | 18:13 | 2.908 EUR | 0.01 | 10 |
Euronext Milan MTF Trading After Hours | 2024/08/14 | 17:44 | 2.924 EUR | 0.00 | 1 |
Euronext Milan MTF Global Equity Market | 2024/08/16 | 12:02 | 2.972 EUR | 0.00 | 3 |
Duesseldorf | 2024/08/16 | 19:30 | 2.904 EUR | 0.00 | 6 |
Berlin | 2024/08/16 | 12:05 | 2.96 EUR | 0.00 | 2 |
CUREVAC NV |
- - |
Friedrich-Miescher-Strasse 15 - 72076 Tübingen |
Telefon: +49-7071-9883-0 |
Fax: +49-7071-9883-1101 |
E-mail: info@curevac.com |
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and protein therapy. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany. |
Alexander Zehnder | Chairman of Managing Board |
Malte Greune | Member of Executive Committee |
Myriam Mendila | Member of Executive Committee |
Pierre Kemula | Member of Executive Committee |
Thaminda Ramanayake | Member of Executive Committee |
Baron Jean Stéphenne | Chairman of Supervisory Board |
Debra Stephanie Barker | Member of Supervisory Board |
Klaus Schollmeier | Member of Supervisory Board |
Mathias Hothum | Member of Supervisory Board |
Viola Bronsema | Member of Supervisory Board |
Birgit Hofmann | Member of Supervisory Board |
Craig Tooman | Member of Supervisory Board |
Michael Brosnan | Member of Supervisory Board |
Any information, material and services regarding financial instruments and securities provided by Erste Group Bank AG or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites”) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions (the “Interested Party“).
The publication and distribution of information as well as offering and selling of products and services described on the Websites is prohibited by law in some jurisdictions. For this reason, persons in countries in which the publication as well as the offering and selling of products and services described on the Websites are not permitted by law, must not enter the Websites and/or acquire the products displayed on the Websites.
Neither Erste Group nor any third party shall offer access to the Websites or offer the products to especially, but not limited to citizen/residents of the United States and “U.S. person” (as defined in Regulation S under the US Securities Act 1933 as amended), citizen/resident of Australia, Canada, Great Britain and Japan. For this reason, the distribution or redistribution of the information, materials and products into United States, Australia, Canada, Great Britain and Japan or into any other jurisdiction where it is not permitted under the applicable law, as well as to the citizens/residents of these countries shall be prohibited.
The securities displayed on the Websites have not been and will not be registered under the US Securities Act of 1933 and trading in the securities has not been approved for purposes of the US Commodities Exchange Act of 1936. For this reason the securities may, inter alia, not be offered, sold or delivered within the United States or, for the account and benefit of U.S. persons.
The Interested Party is solely responsible to examine, whether he may enter the Websites under the law applicable to it. Erste Group shall not be responsible for the distribution of content of any of the Websites to individuals or entities which provide false information about their right to enter the Websites. For this reason Erste Group shall not be liable for any legal claims or damages which may result from the unauthorized entering or reading of the Websites.
By agreeing to this hereto, the Interested Party confirms that
(i) It has read, understood and accepted this Information and the Disclaimer;
(ii) It informed itself about any possible legal restriction and warrants that it is not restricted or prohibited to enter the Websites according to any law applicable; and
(iii) It does not make available the contents of the Websites to any person who is not qualified by law to enter the Websites.
(iV) It is no consumer.